Hematological Malignancies, Solid Tumors
Conditions
Brief summary
This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors
Detailed description
This is a randomized, crossover, open label, phase I study to assess the effect of food on the bioavailability of AXL1717 in advanced cancer patients. A single, oral dose of AXL1717 is to be administered to patients on each of two occasions that are 7-day apart, in random order: after an overnight fast (fasted treatment) and with a high-fat or moderate-fat breakfast (fed treatment).
Interventions
DRUGFasted treatment: AXL1717
DRUGFed treatment: AXL1717
Sponsors
Axelar AB
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be informed of the nature of the study and have provided written informed consent 2. At least 18 years of age 3. Histologically confirmed diagnosis of advanced solid or hematological malignancy not amenable to standard treatment. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 after optimization of analgesics 5. Life expectancy ≥ 3 months 6. Hematology values: blood leukocyte count ≥ 3.0 x 109/L, blood absolute neutrophil count ≥ 1.5 x 109/L, blood platelet count ≥ 100 x109/L, hemoglobin ≥ 100 g/L (transfusions are allowed) 7. Clinical chemistry values: plasma total bilirubin level ≤ 1.5 times the upper limit of the normal range (ULN; i.e. reference), plasma AST or ALT ≤ 1.5 x ULN (≤5 times if liver metastases have been documented) and plasma creatinine ≤ 1.5 x ULN 8. 12-lead ECG with normal tracings; or changes that are not clinically significant and do not require medical intervention
Exclusion criteria
1. Ongoing infection or other major recent or ongoing disease that, according to the Investigator, poses an unacceptable risk to the patient 2. Known primary or secondary central nervous system malignancy. (Patients with symptoms suggestive of possible CNS metastasis such as headache, dizziness or focal neurological deficits should undergo CT or MRI of the brain to rule out CNS metastasis. Patients who do not have CNS symptoms do not need a CT or MRI of the brain.) 3. Grade 3 or higher constipation within the past 28 days or grade 2 constipation within the past 14 days before randomization. (Patients with grade 2 constipation within the past 14 days could be re-screened if constipation decreases to ≤ grade 1 with optimal management of constipation.) 4. Impairment of gastrointestinal (GI) function, GI cancer or GI disease that may significantly alter the absorption of AXL1717 5. Coexisting uncontrolled medical condition, including active cardiac disease (such as unstable angina, myocardial infarction within 6 months, or New York Heart Association Class III/IV congestive heart failure), or significant dementia 6. Hepatic impairment as indicated by abnormalities of transaminases and/or alkaline phosphatase (AST and/or ALT \> 1.5 × upper limit of normal concomitant with alkaline phosphatase \> 2.5 × upper limit of normal, ≤5 times if liver metastases have been documented) 7. Major surgical procedure within 4 weeks prior to randomization 8. Use of potent inhibitors of CYP2C9 (e.g. Fluconazole) from 3 weeks prior to first administration of investigational product 9. Women of child bearing potential (WOCBP) who do not consent to using acceptable methods of contraception (i.e. two of the following - oral contraception, barrier contraception, intrauterine device). For purposes of this study, WOCBP include any female who has experienced menarche, who has not undergone tubal ligation, and who is not postmenopausal. Post menopause is defined as: amenorrhea ≥ 12 consecutive months without another cause. 10. Women who are breast-feeding or have a positive pregnancy test at screening 11. Current participation in any other investigational clinical trial or any administration of an investigational agent within 4 weeks of study drug administration or 10 half-lives of the investigational agent, whichever is longer. Patients with unresolved investigational treatment-related AEs may not participate. 12. Known or suspected hypersensitivity to AXL1717 13. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Single dose AXL1717 serum pharmacokinetic profile under fasting versus fed condition in each patient | several samples within 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Safety of AXL1717 through adverse event reporting | Up to 30 days after last dose of study drug |
Countries
Sweden
Outcome results
None listed